Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini & Roberto Ronca. (2023) Proteasome inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents 0:0, pages 1-22.
Read now
Read now
Rebecca Citrin, Jessica B. Foster & David T. Teachey. (2016) The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Expert Review of Hematology 9:9, pages 873-889.
Read now
Read now
Lukas D. Wartman, Mark A. Fiala, Theresa Fletcher, Emily R. Hawkins, Amanda Cashen, John F. DiPersio, Meagan A. Jacoby, Keith E. Stockerl-Goldstein, Iskra Pusic, Geoffrey L. Uy, Peter Westervelt & Ravi Vij. (2016) A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia & Lymphoma 57:3, pages 728-730.
Read now
Read now
Articles from other publishers (2)
Farhan Azad, Ross Moyer, Clive J Miranda & Matthew Gravina. (2023) Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma. Cureus.
Crossref
Crossref
Lucy Swift, Aarthi Jayanthan, Yibing Ruan, Ronald Anderson, Jessica Boklan, Tanya Trippett & Aru Narendran. (2018) Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib. Targeted Oncology 13:6, pages 779-793.
Crossref
Crossref